Unlike SHMT1, whose role in MASLD-related inflammation and fibrosis remains unclear, SHMT2 has been more clearly implicated in metabolic dysfunction-associated liver disease (Ghrayeb et al., 2024, McBride et al., 2024, Zhang et al., 2023). The gene discussed is SHMT1; the disease is liver disorder.